Quantoom Biosciences

Greater access and autonomy through innovation in bioproduction

We develop open, integrated, affordable and (pre)clinically proven platforms to enable the production of vaccines & therapeutics that scale from development to mass production.

Who We Are

Quantoom Biosciences, a Univercells company, is a biotech embarking on a mission to reinvent bioproduction with open, integrated, affordable and (pre)clinically validated technology platforms.

We are a team of scientists, engineers and clinicians bringing radical innovation to the way we produce vaccines and therapeutics.

Our facilities are strategically located in Belgium, in the heart of Europe, benefiting from an exceptional biotech ecosystem.

Who We Are

Quantoom Biosciences, a Univercells company, is a biotech embarking on a mission to reinvent bioproduction with open, integrated, affordable and (pre)clinically validated technology platforms.

We are a team of scientists, engineers and clinicians bringing radical innovation to the way we produce vaccines and therapeutics.

Our facilities are strategically located in Belgium, in the heart of Europe, benefiting from an exceptional biotech ecosystem.

what we do

At Quantoom Biosciences, we are committed to solve some of the biggest production challenges facing vaccines and therapeutics.

We give our partners greater access to drug development and production autonomy through technical and business model innovation.

We do this by providing our partners with technology platforms that include more parts of the value chain in a single solution.

More specifically, we:

We are currently evaluating several technologies to produce vaccines & other therapeutics.

what we do

At Quantoom Biosciences, we are committed to solve some of the biggest production challenges facing vaccines and therapeutics.

We give our partners greater access to drug development and production autonomy through technical and business model innovation.

We do this by providing our partners with technology platforms that include more parts of the value chain in a single solution.

More specifically, we:

We are currently evaluating several technologies to produce vaccines & other therapeutics.

Our flagship RNA platform

We believe we can solve the challenges of RNA production through disruptive innovation, by delivering greater access and autonomy to this technology.

Despite the rapid uptake of mRNA-based COVID-19 vaccines, the way RNA is synthesized has not significantly advanced since its discovery. Until now, there has not been a simple, scalable and cost-efficient way to produce RNA-based drugs.

Quantoom’s RNA synthesis platform is changing this : We reduce the barriers to production for research labs, biopharma or CDMOs by lowering the costs and know-how needed to make mRNA.

Using the platform, our partners have the freedom to produce any RNA product without being tied to a specific drug developer or major suppliers thanks to the integration of critical components and ongoing work on licensing rights.

We remove barriers to making mRNA-based vaccines and therapeutics from development up to mass production through an open, integrated and affordable platform for the production of mRNA.

Our flagship RNA platform

We believe we can solve the challenges of RNA production through disruptive innovation, by delivering greater access and autonomy to this technology.

Despite the rapid uptake of mRNA-based COVID-19 vaccines, the way RNA is synthesized has not significantly advanced since its discovery. Until now, there has not been a simple, scalable and cost-efficient way to produce RNA-based drugs.

Quantoom’s RNA synthesis platform is changing this : We reduce the barriers to production for research labs, biopharma or CDMOs by lowering the costs and know-how needed to make mRNA.

Using the platform, our partners have the freedom to produce any RNA product without being tied to a specific drug developer or major suppliers thanks to the integration of critical components and ongoing work on licensing rights.

We remove barriers to making mRNA-based vaccines and therapeutics from development up to mass production through an open, integrated and affordable platform for the production of mRNA.

What makes us different

We deliver access and autonomy through innovation
innovation - Disruptive innovation as the driver of everything we do
Access - Lower entry barriers to drug development and production
Autonomy - Self-sufficient production up to commercial scale

What makes us different

We deliver access and autonomy through innovation
innovation - Disruptive innovation as the driver of everything we do
Access - Lower entry barriers to drug development and production
Autonomy - Self-sufficient production up to commercial scale

Enabling more organisations to explore a wider range of
product development opportunities to get to treatments faster.

Enabling more organisations to explore a wider range of product development opportunities to get to treatments faster.

Our Team

Our team consists of international experts whose talent, experience and commitment
position the company as a key player in therapeutic development and biomanufacturing.

Management Team

José Castillo

Chief Executive Officer
(and Univercells Co-Founder)

Sudhir Sharma

Chief Scientific Officer

Kristof Vandekerckhove

Head of Innovation

Yves Ghislain

Head of Technical Development

Conor Cahill

Head of Product Development

Strategic & Scientific Advisory Board